BioVie Inc.: A Clinical-Stage Company Addressing Neurological Disorders and Advanced Liver Disease
On March 27, 2025, BioVie Inc. (NASDAQ: BIVI), a clinical-stage biotech company, made an important announcement regarding its plans to host a virtual investor event. This event will focus on the unmet medical need and current treatment landscape for long COVID, featuring key opinion leader (KOL) Lindsay McAlpine, MD, BSc from Yale University.
About BioVie Inc.
BioVie Inc. is a clinical-stage biotech company based in Carson City, Nevada, dedicated to developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. The company’s mission is to improve the lives of patients suffering from these conditions and generate significant returns for its shareholders.
Long COVID: An Unmet Medical Need
Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), refers to a range of new, ongoing, or worsening health problems experienced after recovery from an acute COVID-19 infection. These symptoms can last weeks or months and may include fatigue, shortness of breath, chest pain, brain fog, and joint pain, among others. There is currently no FDA-approved treatment for long COVID, making it an unmet medical need.
Key Opinion Leader: Dr. Lindsay McAlpine
Dr. Lindsay McAlpine, MD, BSc from Yale University, will join company management during the virtual investor event to discuss the unmet need and current treatment landscape for long COVID. Dr. McAlpine is a highly respected and experienced physician with a focus on neurological disorders and infectious diseases. Her insights and expertise will provide valuable context for BioVie’s ongoing efforts to address this significant medical need.
Impact on Individuals
For individuals who have contracted COVID-19 and are experiencing long-term symptoms, the lack of approved treatments can be frustrating and debilitating. The virtual investor event featuring Dr. McAlpine and BioVie’s management team may shed light on potential treatment options and offer a sense of hope for those affected.
Impact on the World
Long COVID is not only a concern for individuals but also for the global community. With an estimated 10% to 30% of COVID-19 survivors experiencing long-term symptoms, the impact on healthcare systems, economies, and societies could be significant. The virtual investor event hosted by BioVie Inc. may contribute to the ongoing global effort to find effective treatments for long COVID and improve the lives of millions of people worldwide.
Conclusion
BioVie Inc.’s upcoming virtual investor event, featuring key opinion leader Dr. Lindsay McAlpine, presents an opportunity for the company to share its progress in addressing the unmet medical need for long COVID treatments. This event is not only essential for individuals affected by long COVID but also for the global community, as the potential impact on healthcare systems, economies, and societies is significant. By focusing on innovative drug therapies for neurological and neurodegenerative disorders and advanced liver disease, BioVie Inc. is poised to make a positive difference in the lives of patients and create value for its shareholders.
- BioVie Inc. is a clinical-stage biotech company focused on neurological and neurodegenerative disorders and advanced liver disease.
- The company will host a virtual investor event on April 10, 2025, featuring key opinion leader Dr. Lindsay McAlpine from Yale University.
- Long COVID, also known as PASC, is an unmet medical need with no FDA-approved treatment.
- Dr. McAlpine’s expertise in neurological disorders and infectious diseases will provide valuable insights during the event.
- The impact of long COVID on individuals and the global community is significant, making this event essential.
